Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Can Fite Biopharma Ltd (CANF)

Tel Aviv
Symbol
Exchange
Currency
CANFTel AvivILS
CANFNYSEUSD
Currency in ILS
1.9
0.0(0.00%)
Delayed Data
CANF Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
Fair Value
Unlock Value
Day's Range
1.92.0
52 wk Range
1.95.6
Key Statistics
Edit
Bid/Ask
1.90 / 2.00
Prev. Close
1.9
Open
1.9
Day's Range
1.9-2
52 wk Range
1.9-5.6
Volume
6.03M
Average Volume (3m)
15.76M
1-Year Change
-29.63%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CANF Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Technical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
pro lock
Unlock All 10
RSI suggests the stock is in oversold territory
Unlock InvestingPro

Can Fite Biopharma Ltd News & Analysis

Show more

Can Fite Biopharma Ltd Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
8
Market
Israel

Compare CANF to Peers and Sector

Metrics to compare
CANF
Peers
Sector
Relationship
P/E Ratio
−1.5x−0.4x−0.6x
PEG Ratio
−0.030.000.00
Price/Book
4.4x2.0x2.6x
Price / LTM Sales
16.3x2.4x3.2x
Upside (Analyst Target)
-121.3%46.2%
Fair Value Upside
Unlock24.2%7.0%Unlock

Analysts' Recommendations

1 Buy
0 Hold
0 Sell
Ratings:
0 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.0

More details

FAQ

What Is the Can Fite Biopharma (CANF) Stock Price Today?

The Can Fite Biopharma stock price today is 1.90

What Stock Exchange Does Can Fite Biopharma Trade On?

Can Fite Biopharma is listed and trades on the Tel Aviv stock exchange.

What Is the Stock Symbol for Can Fite Biopharma?

The stock symbol for Can Fite Biopharma is "CANF."

What Is the Can Fite Biopharma Market Cap?

As of today, Can Fite Biopharma market cap is 38.84M.

What is Can Fite Biopharma Earnings Per Share?

The Can Fite Biopharma EPS is -0.005.

What Is the Next Can Fite Biopharma Earnings Date?

Can Fite Biopharma will release its next earnings report on Mar 26, 2025.

From a Technical Analysis Perspective, Is CANF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.